Anti-Eastern Equine Encephalitis Virus (Clone: EEEV-138)

Anti-Eastern Equine Encephalitis Virus (Clone: EEEV-138)

Product No.: LT571

- -
- -
Product No.LT571
Clone
EEEV-138
Target
Eastern Equine Encephalitis Virus
Product Type
Recombinant Monoclonal Antibody
Alternate Names
EEEV, Triple E
Isotype
Human IgG1
Applications
ELISA
,
N

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Eastern Equine Encephalitis
Virus
Expression Host
HEK-293 Cells
Immunogen
Sequenced from human survivors of natural EEEV infection.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Standard Overnight on Blue Ice.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
Eastern Equine Encephalitis virus (EEEV), one of the most virulent viruses endemic to North America, is a rare mosquito-borne encephalitic alphavirus in the Togaviridae family. Infection leads to a 30% to 75% mortality rate, and up to 90% of survivors develop ongoing neurologic problems1, 2. On average, seven human cases are confirmed yearly in the United States. EEEV is of particular concern because of its potential aerosol spread and lack of available treatments. EEEV prevalence in mosquitoes that feed on humans has recently increased.

Antigen Details

Research Area
Category B Pathogens
.
Eastern Equine Encephalitis
.
Infectious Disease
.
Viral

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD), Link Text
2. Williamson LE, Gilliland T Jr, Yadav PK, et al. Cell. 183(7):1884-1900.e23. 2020.
3. Kim AS, Austin SK, Gardner CL, et al. Nat Microbiol. 4(1):187-197. 2019.
4. Zhang R, Hryc CF, Cong Y, et al. EMBO J. 30(18):3854-3863. 2011.
5. Voss JE, Vaney MC, Duquerroy S, et al. Nature. 468(7324):709-12. 2010.
6. Li L, Jose J, Xiang Y, et al. Nature. 468(7324):705-8. 2010.
Indirect Elisa Protocol
N

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.